Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agnoist: Protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study - the TAO study

Publikation: KonferencebidragPosterForskning

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@conference{05f91c0722b14009908a9f90b528eda5,
title = "Treatment of antipsychotic-associated obesity with a GLP-1 receptor agnoist: Protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study - the TAO study",
abstract = "Background and aim: Antipsychotic medication is widely associated with dysmetabolism including obesity and type 2 diabetes, cardiovascular-related diseases and early death. Obesity is considered the single most important risk factor for cardiovascular morbidity and mortality. Interventions against antipsychotic-associated obesity are limited and insufficient. Glucagon-like peptide-1 (GLP-1) receptor agonists are approved for the treatment of type 2 diabetes, but their bodyweight lowering effects have also been recognized in non-diabetic patients. The purpose of this trial is to examine if treatment with a GLP-1 receptor agonist (exenatide once-weekly) is safe and facilitates weight loss in non-diabetic schizophrenia patients with antipsychotic-associated obesity.Materials and methods: Forty obese patients with schizophrenia or schizoaffective disorder treated with antipsychotic drugs will be randomised to subcutaneous injection of exenatide once-weekly (2 mg) or placebo for 3 months, adjunctive to their antipsychotic treatment. The primary endpoints are safety and weight loss after 3 months. Secondary endpoints include several metabolic measurements, various psychopathological and cognitive measures, and structural and functional brain magnetic resonance imaging.Results: The study is ongoing.Conclusion: The trial has been approved by the Danish Health and Medicines Authority, the National Committee on Health Research Ethics and the Danish Data Protection Agency. Trial participation presupposes both orally and written patient informed consent. An external, independent monitoring committee (Good Clinical Practice Unit at Copenhagen University Hospital) will monitor the study according to the GCP Guidelines. Trial data, including positive, negative and inconclusive results, will be presented at national and international scientific meetings and conferences. Results are expected to be submitted in peer-reviewed journals in 2015.",
author = "Ish{\o}y, {Pelle Lau} and Knop, {Filip Krag} and Broberg, {Brian Villumsen} and Lone Baandrup and Birgitte Fagerlund and J{\o}rgensen, {Niklas Rye} and Andersen, {Ulrik Bj{\o}rn} and Egill Rostrup and Glenth{\o}j, {Birte Yding} and Ebdrup, {Bj{\o}rn Hylsebeck}",
year = "2014",
month = "10",
day = "8",
language = "English",

}

RIS

TY - CONF

T1 - Treatment of antipsychotic-associated obesity with a GLP-1 receptor agnoist: Protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study - the TAO study

AU - Ishøy, Pelle Lau

AU - Knop, Filip Krag

AU - Broberg, Brian Villumsen

AU - Baandrup, Lone

AU - Fagerlund, Birgitte

AU - Jørgensen, Niklas Rye

AU - Andersen, Ulrik Bjørn

AU - Rostrup, Egill

AU - Glenthøj, Birte Yding

AU - Ebdrup, Bjørn Hylsebeck

PY - 2014/10/8

Y1 - 2014/10/8

N2 - Background and aim: Antipsychotic medication is widely associated with dysmetabolism including obesity and type 2 diabetes, cardiovascular-related diseases and early death. Obesity is considered the single most important risk factor for cardiovascular morbidity and mortality. Interventions against antipsychotic-associated obesity are limited and insufficient. Glucagon-like peptide-1 (GLP-1) receptor agonists are approved for the treatment of type 2 diabetes, but their bodyweight lowering effects have also been recognized in non-diabetic patients. The purpose of this trial is to examine if treatment with a GLP-1 receptor agonist (exenatide once-weekly) is safe and facilitates weight loss in non-diabetic schizophrenia patients with antipsychotic-associated obesity.Materials and methods: Forty obese patients with schizophrenia or schizoaffective disorder treated with antipsychotic drugs will be randomised to subcutaneous injection of exenatide once-weekly (2 mg) or placebo for 3 months, adjunctive to their antipsychotic treatment. The primary endpoints are safety and weight loss after 3 months. Secondary endpoints include several metabolic measurements, various psychopathological and cognitive measures, and structural and functional brain magnetic resonance imaging.Results: The study is ongoing.Conclusion: The trial has been approved by the Danish Health and Medicines Authority, the National Committee on Health Research Ethics and the Danish Data Protection Agency. Trial participation presupposes both orally and written patient informed consent. An external, independent monitoring committee (Good Clinical Practice Unit at Copenhagen University Hospital) will monitor the study according to the GCP Guidelines. Trial data, including positive, negative and inconclusive results, will be presented at national and international scientific meetings and conferences. Results are expected to be submitted in peer-reviewed journals in 2015.

AB - Background and aim: Antipsychotic medication is widely associated with dysmetabolism including obesity and type 2 diabetes, cardiovascular-related diseases and early death. Obesity is considered the single most important risk factor for cardiovascular morbidity and mortality. Interventions against antipsychotic-associated obesity are limited and insufficient. Glucagon-like peptide-1 (GLP-1) receptor agonists are approved for the treatment of type 2 diabetes, but their bodyweight lowering effects have also been recognized in non-diabetic patients. The purpose of this trial is to examine if treatment with a GLP-1 receptor agonist (exenatide once-weekly) is safe and facilitates weight loss in non-diabetic schizophrenia patients with antipsychotic-associated obesity.Materials and methods: Forty obese patients with schizophrenia or schizoaffective disorder treated with antipsychotic drugs will be randomised to subcutaneous injection of exenatide once-weekly (2 mg) or placebo for 3 months, adjunctive to their antipsychotic treatment. The primary endpoints are safety and weight loss after 3 months. Secondary endpoints include several metabolic measurements, various psychopathological and cognitive measures, and structural and functional brain magnetic resonance imaging.Results: The study is ongoing.Conclusion: The trial has been approved by the Danish Health and Medicines Authority, the National Committee on Health Research Ethics and the Danish Data Protection Agency. Trial participation presupposes both orally and written patient informed consent. An external, independent monitoring committee (Good Clinical Practice Unit at Copenhagen University Hospital) will monitor the study according to the GCP Guidelines. Trial data, including positive, negative and inconclusive results, will be presented at national and international scientific meetings and conferences. Results are expected to be submitted in peer-reviewed journals in 2015.

M3 - Poster

ER -

ID: 44614743